myNEO Therapeutics’ CEO, Cedric Bogaert, recently won a spot on the Forbes30under30 List 2023! We are very honored and excited about this achievement. Here is what he had to say about earning the spot. “What started out 6 years ago as experimenting with some...
Lymfklierkanker Vereniging Vlaanderen (LVV) is organizing a webinar on January 28th where Lien Lybaert will explain in understandable language to cancer patients, their loved ones & sympathizers what has fascinated her for 10 years now:...
myNEO Therapeutics will attend job fairs and participate in the following events: J.P. Morgan Annual Healthcare Conference – Oral presentation – San Francisco – January 8 – 10, 2024 Keystone: Cancer ImmunoTherapy – Poster presentation...
myNEO Therapeutics aims this year to double the team in size due to our growing project portfolio with multiple different partners. The data scientist team has been joined by Gitta Boons and Lies van Olmen earlier this year and we are...
CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that combining our tumor characterization and neoantigen target identification methods with an mRNA vaccination technology...
Abera Bioscience, a listed Swedish company with vaccine platforms for prophylactic and therapeutic vaccines today signed an agreement with Belgian company myNEO Therapeutics for collaboration within the neoantigen field. The companies will work closely together to...
